Key Takeaways -
• President Trump’s administration is actively reviewing a proposal to move cannabis from Schedule I to Schedule III of the federal Controlled Substances Act (CSA) and a decision on rescheduling is expected...more
8/21/2025
/ Banking Sector ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Controlled Substances Act ,
Department of Justice (DOJ) ,
Food and Drug Administration (FDA) ,
IRS ,
Marijuana ,
Medical Marijuana ,
Popular ,
Regulatory Reform ,
Research and Development ,
Schedule I Drugs ,
Tax Planning ,
Trump Administration
After 50 years of being on the most restrictive schedule alongside drugs like heroin and PCP, the DEA will move to reschedule marijuana in Schedule III, where the plant’s medical benefits will finally be recognized by the...more
5/1/2024
/ Agribusiness ,
Controlled Substances Act ,
Corporate Counsel ,
DEA ,
Decriminalization of Marijuana ,
Department of Justice (DOJ) ,
Financial Services Industry ,
Food and Drug Administration (FDA) ,
Marijuana ,
Marijuana Related Businesses ,
Medical Marijuana ,
Medical Research ,
Popular ,
Schedule I Drugs
On August 30, 2023, the federal government formally acknowledged the medical use and low potential of abuse for cannabis, with the US Department of Health and Human Services (HHS) recommending that cannabis be rescheduled to...more
9/1/2023
/ Biden Administration ,
Cannabis-Related Businesses (CRBs) ,
Controlled Substances Act ,
Criminal Justice Reform ,
DEA ,
Decriminalization of Marijuana ,
Department of Health and Human Services (HHS) ,
Department of Justice (DOJ) ,
Drug Treatment ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Internal Revenue Code (IRC) ,
IRS ,
Medical Marijuana ,
Medical Research ,
Pharmaceutical Industry ,
Popular ,
Schedule I Drugs ,
Tax Penalties